BMO Capital Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
